目的建立冠心苏合丸（Guanxin Suhe Pill，GXSHP）HPLC内标定量指纹图谱，用内标定量指纹图谱法选出冠心苏合丸对照制剂，为冠心苏合丸的质量控制提供对照制剂控制法。方法采用AgilentPoroshell 120SBC18色谱柱（150mm×4．6mm，2．...目的建立冠心苏合丸（Guanxin Suhe Pill，GXSHP）HPLC内标定量指纹图谱，用内标定量指纹图谱法选出冠心苏合丸对照制剂，为冠心苏合丸的质量控制提供对照制剂控制法。方法采用AgilentPoroshell 120SBC18色谱柱（150mm×4．6mm，2．7μm），流动相为水-甲醇（均含0．2％醋酸），梯度洗脱，体积流量0．5mL／min，柱温（25．00±0．15）℃，紫外检测波长为275nm，进样量5此。采用内标定量指纹法整体鉴定12批次GXSHP（S1～S12）质量，根据本方法评价结果选出冠心苏合丸对照制剂。结果以内标物峰为参照峰，确定36个共有指纹峰，以加入固定浓度内标为基准建立了GXSHP-HPLC内标定量指纹图谱。用内标定量指纹法鉴别出s3、s5～s7、s9质量极好，s4、S8、s10、s11质量很好，s1、s2质量好，S12质量为劣，根据该方法评价结果，最终确定s3、s5～S7、S9可作为冠心苏合丸对照制剂。结论内标定量指纹法可以减少对照品的使用，校正指纹图谱变化，提高测定结果的准确性，选出的对照制剂生成冠心苏合丸对照制剂指纹图谱可用于大批量冠心苏合丸的质量控制，具有重大的实际应用意义。展开更多
The natural history of Barrett's esophagus (BE) is difficult to quantify because,by definition,it should describe the course of the condition if left untreated.Pragmatically,we assume that patients with BE will re...The natural history of Barrett's esophagus (BE) is difficult to quantify because,by definition,it should describe the course of the condition if left untreated.Pragmatically,we assume that patients with BE will receive symptomatic treatment with acid suppression,usually a proton pump inhibitor,to treat their heartburn.This paper describes the development of complications of stricture,ulcer,dysplasia and adenocarcinoma from this standpoint.Controversies over the definition of BE and its implications in clinical practice are presented.The presence of intestinal metaplasia and its relevance to cancer risk is discussed,and the need to measure the extent of the Barrett's epithelium (long and short segments) using the Prague guidelines is emphasized.Guidelines and international consensus over the diagnosis and management of BE are being regularly updated.The need for expert consensus is important due to the lack of randomized trials in this area.After searching the literature,we have tried to collate the important studies regarding progression of Barrett's to dysplasia and adenocarcinoma.No therapeutic studies yet reported show a clear reduction in the development of cancer in BE.The effect of pharmacological and surgical intervention on the natural history of Barrett's is a subject of ongoing research,including the Barrett's Oesophagus Surveillance Study and the aspirin and esomeprazole cancer chemoprevention trial with interesting results.The geographical variation and the wide range of outcomes highlight the difficulty of providing an individualized risk profile to patients with BE.Future studies on the interaction of genome wide abnormalities in Barrett's and their interaction with environmental factors may allow individualization of the risk of cancer developing in BE.展开更多
文摘目的建立冠心苏合丸（Guanxin Suhe Pill，GXSHP）HPLC内标定量指纹图谱，用内标定量指纹图谱法选出冠心苏合丸对照制剂，为冠心苏合丸的质量控制提供对照制剂控制法。方法采用AgilentPoroshell 120SBC18色谱柱（150mm×4．6mm，2．7μm），流动相为水-甲醇（均含0．2％醋酸），梯度洗脱，体积流量0．5mL／min，柱温（25．00±0．15）℃，紫外检测波长为275nm，进样量5此。采用内标定量指纹法整体鉴定12批次GXSHP（S1～S12）质量，根据本方法评价结果选出冠心苏合丸对照制剂。结果以内标物峰为参照峰，确定36个共有指纹峰，以加入固定浓度内标为基准建立了GXSHP-HPLC内标定量指纹图谱。用内标定量指纹法鉴别出s3、s5～s7、s9质量极好，s4、S8、s10、s11质量很好，s1、s2质量好，S12质量为劣，根据该方法评价结果，最终确定s3、s5～S7、S9可作为冠心苏合丸对照制剂。结论内标定量指纹法可以减少对照品的使用，校正指纹图谱变化，提高测定结果的准确性，选出的对照制剂生成冠心苏合丸对照制剂指纹图谱可用于大批量冠心苏合丸的质量控制，具有重大的实际应用意义。
文摘The natural history of Barrett's esophagus (BE) is difficult to quantify because,by definition,it should describe the course of the condition if left untreated.Pragmatically,we assume that patients with BE will receive symptomatic treatment with acid suppression,usually a proton pump inhibitor,to treat their heartburn.This paper describes the development of complications of stricture,ulcer,dysplasia and adenocarcinoma from this standpoint.Controversies over the definition of BE and its implications in clinical practice are presented.The presence of intestinal metaplasia and its relevance to cancer risk is discussed,and the need to measure the extent of the Barrett's epithelium (long and short segments) using the Prague guidelines is emphasized.Guidelines and international consensus over the diagnosis and management of BE are being regularly updated.The need for expert consensus is important due to the lack of randomized trials in this area.After searching the literature,we have tried to collate the important studies regarding progression of Barrett's to dysplasia and adenocarcinoma.No therapeutic studies yet reported show a clear reduction in the development of cancer in BE.The effect of pharmacological and surgical intervention on the natural history of Barrett's is a subject of ongoing research,including the Barrett's Oesophagus Surveillance Study and the aspirin and esomeprazole cancer chemoprevention trial with interesting results.The geographical variation and the wide range of outcomes highlight the difficulty of providing an individualized risk profile to patients with BE.Future studies on the interaction of genome wide abnormalities in Barrett's and their interaction with environmental factors may allow individualization of the risk of cancer developing in BE.
